Conversion Right Triggered for LabCorp’s Zero Coupon Convertible Subordinated Notes Due 2021

BURLINGTON, N.C. --(BUSINESS WIRE)--Jan. 2, 2014-- Laboratory Corporation of America ® Holdings (LabCorp ® ) (NYSE:LH) announced today that its Zero Coupon Convertible Subordinated Notes due 2021 (Zero Coupon Notes) may be converted as set forth below.

LabCorp Updates 2013 Guidance and Provides Preliminary 2014 Guidance

BURLINGTON, N.C. --(BUSINESS WIRE)--Dec. 10, 2013-- Laboratory Corporation of America ® Holdings (LabCorp ® ) (NYSE: LH) today reaffirmed its prior revenue growth guidance of approximately 3% and updated its non-GAAP full year 2013 Adjusted Earnings Per Share (EPS) Excluding Amortization guidance

LabCorp to Offer the IntelliGENTM Multi-Gene Oncology Panel on the Next Generation Sequencing Platform

BURLINGTON, N.C. --(BUSINESS WIRE)--Dec. 9, 2013-- Laboratory Corporation of America ® Holdings (LabCorp ® ) (NYSE: LH) announced today the launch of a new oncology panel on its next generation sequencing (NGS) platform. The IntelliGEN assay improves sensitivity and detection rates for somatic

LabCorp Announces the Availability of Hepatitis C Virus Q80k Polymorphism Screening for the Newly Approved Drug OLYSIO™ (simeprevir)

BURLINGTON, N.C. --(BUSINESS WIRE)--Dec. 3, 2013-- Laboratory Corporation of America ® Holdings (LabCorp ® ) (NYSE: LH) announced today the immediate availability of an enhanced version of its HCV GenoSure ® NS3/4, a drug resistance test that screens for the Q80K polymorphism.

LabCorp to Offer BRCAssureSM Breast Cancer Mutation Tests

BURLINGTON, N.C. --(BUSINESS WIRE)--Dec. 2, 2013-- Laboratory Corporation of America ® Holdings (LabCorp ® ) (NYSE: LH) announced today the nationwide availability of a suite of tests to identify patients with BRCA mutations who are at increased risk for breast, ovarian and other cancers.

LabCorp Announces the Availability of a 4th Generation HIV Assay to Allow the Earlier Detection of Acute HIV Infection

BURLINGTON, N.C. --(BUSINESS WIRE)--Nov. 6, 2013-- Laboratory Corporation of America ® Holdings (LabCorp ® ) (NYSE: LH) announced today the availability of a 4 th generation HIV antigen/antibody combination assay and a new diagnostic algorithm that improves screening for HIV infection.

LabCorp Prices $400 Million in 2.50% Senior Notes Due 2018 and $300 Million in 4.00% Senior Notes Due 2023

BURLINGTON, N.C. --(BUSINESS WIRE)--Oct. 29, 2013-- Laboratory Corporation of America ® Holdings (LabCorp ® ) (NYSE:LH) announced today that it has priced its offering of $700 million in senior notes. The offering consists of two tranches: $400 million aggregate principal amount of 2.50% Senior

LabCorp Announces Proposed Sale of Senior Notes

BURLINGTON, N.C. --(BUSINESS WIRE)--Oct. 29, 2013-- Laboratory Corporation of America ® Holdings (LabCorp ® ) (NYSE: LH) announced today that it plans to offer, subject to market and other conditions, senior notes that are expected to be issued in two tranches with maturities of 5 and 10 years (the

Garheng Kong Named to LabCorp® Board of Directors

BURLINGTON, N.C. --(BUSINESS WIRE)--Oct. 28, 2013-- Laboratory Corporation of America ®  Holdings (LabCorp ® ) (NYSE:LH) today announced that Garheng Kong, MD, PhD, has been appointed to its Board of Directors, effective December 1, 2013. “We are delighted that Garheng has accepted our invitation

Labcorp to offer new FDA-approved companion diagnostic for colorectal cancer

BURLINGTON, N.C. --(BUSINESS WIRE)--Oct. 25, 2013-- Laboratory Corporation of America ® Holdings (LabCorp ® ) (NYSE: LH) announced today the nationwide availability of QIAGEN’s therascreen ® KRAS RGQ PCR Kit, a new FDA -approved companion diagnostic for certain colorectal cancer patients.